Leading US psychiatric experts join Oryzon’s Clinical Advisory Board (CAB) to advance Phase III development of vafidemstat in Borderline Personality Disorder (BPD) CAB and Oryzon establish primary and ...
Discover why decades of research now challenge the BPD diagnosis — and how new models may offer clearer, less stigmatizing ways forward.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results